{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T09:40:18Z","timestamp":1795081218401,"version":"4.10.2"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen Pharma SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021564","name":"National Federation of French Cancer Centres","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.eururo.2025.07.019","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T06:16:56Z","timestamp":1755238616000},"page":"510-518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4730-1161","authenticated-orcid":false,"given":"Nicolas","family":"Demogeot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Salleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Gu\u00e9rif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"de Crevoisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Hannoun-Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Cretin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Sahki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazid","family":"Belkacemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Azria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Pommier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"L\u00e9ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Beckendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Dubray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.07.019_b0005","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.07.019_b0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2022.04.003","article-title":"High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as treatment intensification for localized prostate cancer: an individual patient\u2013data network meta-analysis from the MARCAP Consortium","volume":"82","author":"Kishan","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.07.019_b0015","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/0360-3016(88)90224-6","article-title":"The effect of dose on local control of prostate cancer","volume":"15","author":"Hanks","year":"1988","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.07.019_b0020","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0360-3016(97)00508-7","article-title":"External beam radiotherapy dose response of prostate cancer","volume":"39","author":"Pollack","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.07.019_b0025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0360-3016(00)00691-X","article-title":"Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer-preliminary results","volume":"48","author":"Bey","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.07.019_b0030","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0360-3016(98)00091-1","article-title":"Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer","volume":"41","author":"Zelefsky","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.07.019_b0035","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","article-title":"Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991","volume":"34","author":"Bolla","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.07.019_b0040","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1200\/JCO.21.00855","article-title":"Short androgen suppression and radiation dose escalation in prostate cancer: 12-year results of EORTC trial 22991 in patients with localized intermediate-risk disease","volume":"39","author":"Bolla","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.07.019_b0045","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2020.10.023","article-title":"Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial","volume":"143","author":"Nabid","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2025.07.019_b0050","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1200\/JCO.22.02390","article-title":"Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: results of a phase III multi-institutional trial","volume":"41","author":"Krauss","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.07.019_b0055","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.07.019_b0060","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2025.07.019_b0065","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.1997.03540420041027","article-title":"Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update","volume":"277","author":"Partin","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2025.07.019_b0070","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70\u00a0Gy versus 80\u00a0Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.07.019_b0075","doi-asserted-by":"crossref","unstructured":"LENT SOMA tables. Radiother Oncol 1995;35:17\u201360.","DOI":"10.1016\/0167-8140(95)90055-1"},{"issue":"Suppl 4","key":"10.1016\/j.eururo.2025.07.019_b0080","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S0959-8049(01)00448-8","article-title":"EORTC Quality of Life Group, Quality of Life Unit. Quality of life research within the EORTC\u2014the EORTC QLQ-C30","volume":"38","author":"Fayers","year":"2002","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.eururo.2025.07.019_b0085","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol."},{"key":"10.1016\/j.eururo.2025.07.019_b0090","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.eururo.2025.07.019_b0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.07.019_b0100","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.eururo.2025.07.019_b0105","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.07.019_b0110","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.07.019_b0115","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.07.019_b0120","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0360-3016(01)01579-6","article-title":"Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate","volume":"50","author":"Pilepich","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.07.019_b0125","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(15)70045-8","article-title":"High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial","volume":"16","author":"Zapatero","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.07.019_b0130","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","article-title":"Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG Oncology RTOG 9202","volume":"98","author":"Lawton","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.07.019_b0135","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(18)30757-5","volume":"20","author":"Denham","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.07.019_b0140","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/593241","article-title":"Factors implicated in radiation therapy failure and radiosensitization of prostate cancer","volume":"2012","author":"Bonkhoff","year":"2012","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.eururo.2025.07.019_b0145","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.22.00970","article-title":"Sequencing of androgen-deprivation therapy of short duration with radiotherapy for nonmetastatic prostate cancer (SANDSTORM): a pooled analysis of 12 randomized trials","volume":"41","author":"Ma","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.07.019_b0150","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.29983","article-title":"Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial","volume":"122","author":"Viani","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2025.07.019_b0155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41391-023-00653-7","article-title":"Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: a secondary analysis of RTOG 0415","volume":"27","author":"Carpenter","year":"2024","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.eururo.2025.07.019_b0160","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ijrobp.2024.05.032","article-title":"Helical tomotherapy versus 3-dimensional conformal radiation therapy in high-risk prostate cancer: a phase 3 randomized controlled trial","volume":"120","author":"Roy","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.07.019_b0165","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.07.019_b0170","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825004361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825004361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T22:27:39Z","timestamp":1760048859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825004361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0302283825004361"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.07.019","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}